Showing 7971-7980 of 9809 results for "".
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there ar
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Merz Aesthetics Calls for Entries for First-Ever Innovation Forumhttps://practicaldermatology.com/news/merz-aesthetics-calls-for-entries-for-first-ever-innovation-forum/2460618/Merz Aesthetics is launching its first-ever Innovation Forum with a call for abstract submissions seeking the most creative and inventive medical aesthetics abstracts from the next generation of researchers and healthcare professionals. The author of the winning abstrac
- Online Booking Functionality Comes to Demandforcehttps://practicaldermatology.com/news/online-booking-functionality-comes-to-demandforce/2460615/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche
- AAD Names Drs. Daval Bhanusali and Cory Maughan Patient Care Heroes for Treating Young Dog Bite Victimhttps://practicaldermatology.com/news/aad-names-drs-daval-bhanusali-and-cory-maughan-patient-care-heroes-for-treating-young-dog-bite-victim/2460611/Dhaval Bhanusali, MD, FAAD, and Cory Maughan, DO, FAAD, are American Academy of Dermatology (AAD) Patient Care Heroes for providing life-changing scar treatment to a young dog bite victim. Six-year-old Bridger Walker acted quickly and courageously when a dog tried to attack hi
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi